BSSM Endorses Enclomiphene Use for Male Hypogonadism

The British Society of Sexual Medicine (BSSM) published its first formal position statement on enclomiphene in February 2026 -- and for an unlicensed therapy that has lived in regulatory limbo for over a decade, it is the closest thing to mainstream society endorsement enclomiphene has ever received.

The statement, authored by Foster, Choo, Patel, Kirby, and Hackett in the World Journal of Men's Health, stops short of recommending routine use. But it explicitly identifies enclomiphene as a legitimate option for selected men with secondary hypogonadism -- particularly those who want to preserve fertility or cannot tolerate injectable or topical testosterone.

Key Takeaways

• BSSM published its first enclomiphene position statement in February 2026
• Endorses use only by experienced clinicians in specialist or research settings
• Targets men with secondary hypogonadism who want fertility preservation or are intolerant of standard TRT formats
• Confirms enclomiphene remains unlicensed in the UK and unapproved by the FDA
• Calls evidence "limited" and warns against routine use outside specialist clinics
• Does not change U.S. regulatory status -- compounding pharmacies remain the only legal source

What the BSSM Position Statement Actually Says

The statement is short and deliberately narrow. It does not declare enclomiphene a first-line therapy. It does not recommend it for general practice. What it does is far more practical: it draws a clinical lane in which experienced clinicians can prescribe enclomiphene without operating outside society guidance.

The BSSM defines that lane around four criteria:

1. Secondary hypogonadism only. The patient must have low testosterone driven by reduced pituitary signalling -- low or low-normal LH and FSH -- not primary testicular failure.
2. Fertility preservation as a primary goal. This is the strongest indication. Conventional TRT suppresses spermatogenesis within weeks; enclomiphene maintains it.
3. Specialist setting. The statement explicitly limits use to "experienced clinicians within specialist or research settings." General practice is not the intended venue.
4. Patient counselling on unlicensed status. Patients must be told the drug is not licensed in the UK and not approved by the FDA, and must consent to that.

The society also flagged what enclomiphene is not a candidate for: primary hypogonadism, men with normal LH and FSH despite low testosterone, and routine off-label substitution for standard TRT in men without fertility goals.

Why This Matters Now

For over a decade, enclomiphene has occupied an awkward space. The pharmacology is clean, the human safety record is reasonable, and the fertility-preservation case is uncontested. But the FDA rejected the new drug application in 2015 over manufacturing and clinical-data concerns, and no sponsor has resubmitted since.

That left enclomiphene as a compound-only drug in the U.S. and an unlicensed import in most of Europe. Mainstream urology and endocrinology societies have largely declined to take a position, leaving prescribers to make individual judgments without society backing.

The BSSM statement breaks that silence. It is the first major Western society to formally describe a clinical lane for the drug.

What Changed in the Evidence Base

The position statement leans on a small but consistent body of evidence:

• Wiehle et al. (2014). Phase II randomized trial in men with secondary hypogonadism showed enclomiphene normalized testosterone levels while preserving sperm counts; topical testosterone normalized levels but suppressed sperm counts. (PMID: 25044085)
• Kim et al. (2016). Two Phase III trials in obese hypogonadal men confirmed the same pattern. Enclomiphene raised testosterone, raised LH and FSH, and kept sperm counts in the normal range. Topical testosterone suppressed all three. (PMID: 26496621)
• Real-world cohort data (2019-2024). Smaller observational studies in specialist clinics have reported similar testosterone elevations with low side-effect rates.

The Phase III trials are now nearly a decade old. The BSSM statement frames the evidence as "limited" precisely because no sponsor has run the long-term safety and fertility-outcome studies that would clear regulatory bars.

The Specialist-Only Recommendation

The "specialist or research settings" language is the single most important constraint in the document. The BSSM is not endorsing telehealth-style mass prescribing. It is endorsing thoughtful, lab-driven use by clinicians who understand the HPG axis and can monitor LH, FSH, estradiol, and sperm parameters over time.

That is a meaningful gap from how enclomiphene is often marketed in U.S. telehealth -- as a "natural" or "fertility-friendly" alternative offered to almost anyone who walks into the funnel. The BSSM position effectively challenges that approach without naming it.

How Enclomiphene Differs from TRT in One Picture

The core mechanism difference is the entire reason enclomiphene exists as a separate therapeutic category.

Variable	Enclomiphene	Standard TRT
Mechanism	SERM blocks estrogen feedback at hypothalamus/pituitary	Exogenous testosterone replaces endogenous production
LH / FSH	Increased	Suppressed (often near zero)
Spermatogenesis	Preserved	Suppressed within weeks
Testicular volume	Maintained	Typically shrinks 10-20% in year 1
Route	Oral capsule, daily	Injection (typical), gel, pellet, oral
Stopping	Levels return to baseline within weeks	Variable HPG recovery, often months
Estradiol	May rise (managed by titration)	Variable, often manageable
Regulatory status	Compounded only in U.S., unlicensed in UK	FDA-approved, multiple licensed products

The single most important row is spermatogenesis. For a man under 45 who wants children in the foreseeable future, that row alone often determines the choice -- and the BSSM statement validates that decision pathway.

For a deeper comparison of how to choose between these two approaches based on your specific labs and goals, read our enclomiphene vs TRT guide.

Who the BSSM Statement Targets

Reading the statement closely, four patient profiles fit cleanly:

1. Men in their 30s and early 40s with secondary hypogonadism

This is the prototypical candidate. Total testosterone under 300 ng/dL, low or low-normal LH and FSH, intact testes, no identifiable pituitary disease, and either active fertility goals or future fertility goals. Enclomiphene preserves the option of fathering children without adjunct medications.

2. Men who failed TRT due to side effects

A subset of men cannot tolerate injectable or topical testosterone -- skin reactions to gels, injection-site issues, supraphysiologic estradiol responses, or persistent hematocrit problems. The BSSM acknowledges this group as legitimate enclomiphene candidates.

3. Men coming off TRT who need HPG-axis restart

Although the BSSM does not specifically endorse "post-cycle" use, the underlying mechanism makes enclomiphene a logical tool for restoring endogenous production after exogenous testosterone has shut down the pituitary. This is the clinical scenario behind most off-label use today. Read our coming off TRT guide for how this fits a broader exit protocol.

4. Younger men who want to optimize testosterone without injections

Men in their 20s and 30s with mildly low or low-normal testosterone, intact fertility, and a strong preference for an oral therapy. The BSSM is more cautious about this group, framing it as a specialist judgment call rather than a clear indication.

Who the Statement Does Not Cover

The BSSM explicitly excludes routine use for:

• Men with primary hypogonadism (testes cannot respond to LH regardless of input)
• Men over 60 with established age-related decline (less response, longer trial needed)
• Men with elevated baseline LH/FSH
• Men with normal testosterone seeking "optimization" rather than treatment
• General-practice prescribing without specialist oversight

What This Means for U.S. Patients

Three things to understand if you are reading this in the United States.

1. The Regulatory Status Has Not Changed

The BSSM is a UK society. Its position statement carries clinical weight in the UK and EU specialist community. It does not change FDA status. As of April 2026, enclomiphene is still:

• Not FDA-approved
• Not on the FDA's accelerated review pathway (unlike testosterone for idiopathic hypogonadism, where the FDA invited supplemental NDAs in April 2026)
• Available only through 503A or 503B compounding pharmacies, which can dispense it on individual prescription

If you obtain enclomiphene in the U.S., you are receiving a compounded product, not a manufactured FDA-approved drug.

2. Telehealth Access Is Real but Variable

Several U.S. telehealth clinics offer enclomiphene as part of their formulary. Quality varies widely. The good ones do four things:

1. Order full HPG-axis labs (total and free testosterone, LH, FSH, estradiol, prolactin, SHBG) before prescribing
2. Confirm secondary -- not primary -- hypogonadism through that pattern
3. Counsel explicitly on off-label and compounded status
4. Monitor labs at 6 weeks and 3-6 months, with sperm analysis available on request

The poor ones treat enclomiphene as an over-the-counter substitute for testing. Avoid those.

Compare clinics that handle enclomiphene properly at our best online TRT clinic guide. For warning signs to avoid, see TRT clinic red flags.

3. Insurance Will Not Cover It

Compounded enclomiphene is essentially never covered by U.S. insurance. Cash-pay pricing through telehealth clinics typically ranges from $80 to $180 per month, depending on dose and pharmacy. That places it in similar territory to cash-pay TRT but without the long-term FDA approval clock that may eventually lower TRT prices through insurance leverage.

For how this slots into broader treatment economics, see our TRT pricing guide and insurance vs cash-pay breakdown.

How to Talk to a Clinic About Enclomiphene

If your situation fits the BSSM-described profile -- secondary hypogonadism, fertility goals, or TRT intolerance -- the conversation with a clinic should be specific.

Bring four data points:

1. Two morning total testosterone results, fasted, on different days
2. LH and FSH results from the same panels
3. Estradiol (sensitive assay), prolactin, and SHBG
4. A clear statement of your goal -- preserve fertility, avoid injections, restart HPG axis after TRT, or initial trial before considering TRT

Ask the clinic three questions:

1. Do you prescribe enclomiphene through a 503A or 503B compounding pharmacy? Which one?
2. What is your baseline-to-6-week and 6-week-to-6-month lab schedule?
3. If enclomiphene does not normalize my testosterone within 12 weeks, what is your stepwise alternative?

A clinic that cannot answer all three is not the clinic to use. A clinic that answers cleanly will likely be one of the ones we evaluate at thetrtcatalog.com/clinics.

For a broader view of how this decision interacts with TRT fertility planning -- including the role of hCG, GnRH agonists, and combined protocols -- the fertility guide is the next read.

What the BSSM Statement Does Not Settle

Three open questions remain after February 2026.

Long-Term Safety Beyond Two Years

The Phase III data covers months, not years. The BSSM correctly notes that long-term safety -- particularly cardiovascular, bone density, and prostate -- is not adequately characterized for enclomiphene specifically. The drug acts through a different mechanism than testosterone, so TRAVERSE-class cardiovascular safety data does not directly apply.

Effect on Erectile Function and Mood

The most consistent BSSM-endorsed benefit is biochemical -- raising testosterone while preserving sperm. The functional outcomes (libido, erectile function, mood, energy) are less well-characterized in randomized data than in TRT. Many men report excellent functional response. Others report normalized labs without functional improvement. The mechanism for that gap is unclear.

When (or If) FDA Approval Will Arrive

No U.S. sponsor has signaled intent to resubmit. The 2025-2026 FDA wave -- TRT label expansion, removed boxed warnings, idiopathic hypogonadism pathway -- has not extended to SERMs for male hypogonadism. The BSSM statement is unlikely to trigger that on its own.

Bottom Line

The British Society of Sexual Medicine just gave enclomiphene something it has lacked for a decade: a defined clinical lane endorsed by a recognized society.

For men in that lane -- secondary hypogonadism, fertility preservation, TRT intolerance, or HPG-axis restart -- the statement removes a key barrier. Enclomiphene is now a society-recognized option to discuss with a specialist, not a fringe compound to defend.

For men outside that lane, the message is the opposite. The BSSM is signaling that routine, off-label, telehealth-style enclomiphene prescribing -- without specialist oversight, without HPG-axis labs, without explicit counselling on unlicensed status -- is not what the evidence supports.

If you think your situation fits the lane, two practical next steps:

1. Get the right labs. Total and free testosterone, LH, FSH, estradiol, prolactin, SHBG -- read our how to test testosterone guide for the protocol.
2. Choose a clinic that handles it correctly. Compare options at best online TRT clinic 2026 and screen for the four quality markers listed above.

The BSSM did not declare enclomiphene a winner. It declared it a legitimate tool, in the right hands, for the right patients. That is a meaningful change in the regulatory weather.

References

1. Foster J, Choo L, Patel A, Kirby M, Hackett G. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism. World J Mens Health. 2026.
2. Wiehle RD, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PMID: 25044085.
3. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID: 26496621.
4. Saffati G, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024.
5. British Menopause Society. Tool for Clinicians: Testosterone Replacement in Menopause (January 2026 update).
6. FDA. Class-Wide Labeling Changes for Testosterone Products. February 2025.
7. FDA. FDA Takes Step Forward on Testosterone Therapy for Men. Press Announcement, April 16, 2026.
8. Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (The Testosterone Trials). N Engl J Med. 2016;374(7):611-624.